financetom
Business
financetom
/
Business
/
OpenAI's annualized revenue hits $10 billion, up from $5.5 billion in December 2024
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
OpenAI's annualized revenue hits $10 billion, up from $5.5 billion in December 2024
Jun 9, 2025 12:52 PM

June 9 (Reuters) - OpenAI said on Monday that its

annualized revenue run rate surged to $10 billion as of June,

positioning the company to hit its full-year target amid booming

AI adoption.

Its projected annual revenue figure based on current revenue

data, which was about $5.5 billion in December 2024, has

demonstrated strong growth as the adoption and use of its

popular ChatGPT artificial-intelligence models continue to rise.

This means OpenAI is on track to achieve its revenue target

of $12.7 billion in 2025, which it had shared with investors

earlier.

The $10 billion figure excludes licensing revenue from

OpenAI-backer Microsoft ( MSFT ) and large one-time deals, an

OpenAI spokesperson confirmed. The details were first reported

by CNBC.

Considering the startup lost about $5 billion last year,

OpenAI's revenue milestone shows how far ahead the company is in

revenue scale compared to its competitors, which are also

benefiting from growing AI adoption.

Anthropic recently crossed $3 billion in annualized revenue

on booming demand from code-gen startups using its models.

OpenAI said in March it would raise up to $40 billion in a

new funding round led by SoftBank Group, at a $300

billion valuation.

In more than two years since it rolled out its ChatGPT

chatbot, the company has introduced a bevy of subscription

offerings for consumers as well as businesses.

OpenAI had 500 million weekly active users as of the end of

this March.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Google agrees $36 million fine for anti-competitive deals with Australia telcos
Google agrees $36 million fine for anti-competitive deals with Australia telcos
Aug 17, 2025
SYDNEY, Aug 18 (Reuters) - Google agreed on Monday to pay a A$55 million ($35.8 million) fine in Australia after the consumer watchdog found it had hurt competition by paying the country's two largest telcos to pre-install its search application on Android phones, excluding rival search engines. The fine extends a bumpy period for the Alphabet-owned internet giant in Australia,...
LKQ Europe Forms Joint Venture With IAA's Synetiq
LKQ Europe Forms Joint Venture With IAA's Synetiq
Jun 24, 2025
09:03 AM EDT, 06/24/2025 (MT Newswires) -- LKQ (LKQ) said Tuesday that its LKQ Europe unit has formed an automotive parts and salvage joint venture with IAA unit Synetiq. LKQ said the joint venture, called LKQ Synetiq, will contribute to the development of Europe salvage operations as well as help meet end-of-life vehicle and battery-recycling regulations. The company said the...
McDonald's, Krispy Kreme to end US donut sale partnership as costs mount
McDonald's, Krispy Kreme to end US donut sale partnership as costs mount
Jun 24, 2025
(Reuters) -McDonald's and donut maker Krispy Kreme said on Tuesday they would end their partnership in the United States by July, as the companies struggled to manage the costs associated with the venture. Under the partnership, announced in March last year, McDonald's planned to sell Krispy Kreme's donuts as part of its breakfast menu at more than 14,000 stores in...
Why InMed's Alzheimer's Drug Candidate Is Fueling Sudden Stock Surge
Why InMed's Alzheimer's Drug Candidate Is Fueling Sudden Stock Surge
Jun 24, 2025
InMed Pharmaceuticals Inc. ( INM ) stock is surging early Tuesday, with a session volume of 6.63 million compared to the average volume of 1.31 million, as per data from Benzinga Pro. On Tuesday, InMed released new preclinical data demonstrating that INM-901 significantly reduces inflammation in ex vivo models of neuroinflammation, further supporting its potential as a therapeutic candidate for...
Copyright 2023-2026 - www.financetom.com All Rights Reserved